Heart Rhythm 2017 – Chicago, Illinois

Chicago, May 10th, 2017  – Today MedLumics is attending HRS 2017 in Chicago. From the 10th until the 12th May, Medlumics will be at the Heart Rhythm Scientific Sessions in Chicago, where we will be presenting our new technology: AblaView. Visit us at stand nr. 547.

Heart Rhythm 2017 - Chicago, Illinois

“CAUTION – AblaView® Ablation Catheter is a device for investigational use only in laboratory animals and other tests that do not involve human subjects. The purposed intended use of AblaView Ablation Catheter is the treatment of drug refractory symptomatic paroxysmal atrial fibrillation, when used in conjunction with a compatible radiofrequency generator, a compatible irrigation pump and three-dimensional mapping system. Caution: Federal law restricts this device to sale by or on the order of a physician. Medlumics S.L. is a pre-commercial, medical device company that design and manufactures catheter-based systems for the treatment of supra-ventricular tachycardias. Medlumics products are currently for investigation purposes and are intended to be used by trained professionals. MedLumics is committed to transform progress in the science and technology of light into high-quality innovative products improving human living standards worldwide.”
Manufacturer: Medlumics S.L.
Place of business: Ronda de Poniente 6, 2A. 28760 Tres Cantos, Spain (2017-04-20)


MedLumics Secures 34.4 Million Euros in Series B Funding

Madrid, March 20th, 2017 – MedLumics, a cardiac device company specializing in optically guided minimally invasive instruments, announced today that it has raised 34.4 million Euros in financing that will be used to help advance the product and clinical development of the company’s AblaView catheter, intended for the treatment of atrial fibrillation (AF) and other arrhythmias. This financing is the largest in the history of medtech in Spain and one of the largest in Europe this year.

Continue reading →

MedLumics Appoints Cardiovascular Device Expert Tim Lenihan to Board of Directors

Madrid, January 11th, 2016 – MedLumics, a cardiology device company specializing in the application of advanced optical coherence tomography (OCT) technology, has announced the appointment of cardiovascular device veteran Tim Lenihan to its board of directors. With vast experience in field of electrophysiology, Lenihan will help guide the continued advancement of the company’s catheter ablation technology for the treatment of atrial fibrillation.

Continue reading →

NITID (optical coherence tomography and digital dermatoscope handheld device) – CE Mark approval received

Madrid, September 15th, 2015 – DermaLumics, a recently founded spin-off of optical tomography systems developer MedLumics, announces that NITID, its first skin diagnostic solution, received CE Mark approval in Europe. NITID employs platform technology developed by MedLumics, miniaturizing optical coherence tomography systems into a small chip through integrated optics. NITID is a breakthrough and cuttingedge diagnostic imaging solution for Dermatology that will provide doctors with exceptional results and ease of use, improving patient flow and bringing pathology analysis closer to the patient.

Continue reading →

MedLumics Introduces NITID Skin Imaging System at EADV

MADRID – Oct. 23, 2014

MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, debuted its NITIDTM skin imaging system at the 23rd Annual European Academy of Dermatology and Venereology Congress in Amsterdam. NITID is a handheld diagnostic device designed to help dermatologists quickly and minimally invasively diagnose skin cancer. Once approved by regulatory bodies, it will be the first point-of-care OCT imaging device that can produce dynamic, real-time, high-resolution diagnostic images with tissue penetration capability of up to two millimeters.
Continue reading →

MedLumics Announces “BiopsyPen Project” with €3.6M EU in Funding; Initiative Aimed at New Clinical Applications for Optical Coherence Tomography

MADRID – March 25, 2014 – MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, today announced the kick off of a three-year initiative to translate the latest OCT research into new clinical applications.

Called the “BiopsyPen Project,” the effort is led by MedLumics and the Medical University of Vienna, with participation from a consortium of European members including VTT Finland, Delft University of Technology, Exalos AG, the Polytechnic University of Madrid, and Optocap Ltd. Together, the organizations are working to develop the second generation of a compact handheld diagnostic imaging system that will radically transform the capability of biophotonic technologies for point-of- care diagnosis in dermatology.

“This unique collaboration of leading European technology and clinical centers will allow us to significantly extend the technical possibilities and clinical indications of our micro-chip based OCT system,” said Eduardo Margallo, president and co- founder of MedLumics.

Continue reading →

MedLumics ISO 9001 Certification

Madrid, February 1st, 2014  – MedLumics has obtained the ISO 9001 certificate for the research, design and development of OCT medical imaging devices based on advanced integrated optics, for the purposes of: Dermatology imaging and diagnosis and Image guide RF ablation for treatment of atrial fibrillation.

ISO 9001 Certification

MedLumics Expands Management Team in Preparation for 2014 Launch of First Generation Diagnostic Imaging System for Dermatology

Madrid, January 22nd, 2014  – MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of Miguel Eslava to the new position of vice president and chief operating officer. With more than a decade of senior management experience at GE Healthcare, Mr. Eslava brings significant business operations expertise to the company in advance of the anticipated launch of the first point-of-care diagnostic imaging system for dermatology in the second half of 2014.

“We expect Miguel to play a critical role at MedLumics as we move from a research and development stage company to a commercial organization,” said Eduardo Margallo, president and co-founder of MedLumics. “His knowledge and experience will be invaluable as we build the infrastructure to support the launch of our first diagnostic imaging system for dermatology.”

During his 12-year tenure at GE Healthcare, Mr. Eslava held senior management positions at both a national and international level. Most recently, he was president of GE Healthcare Spain and Portugal, a group including GE Medical Systems S.A., GE Medical Systems Information Technology S.A., Datex Ohmeda S.L., Amersham Health S.A. and Amersham Health Radiofarmacos S.L. He previously served as general sales manager for GE Medical Systems Spain and Portugal, and held other responsibilities within the GE group, including general services manager for GE Medical Systems, vice president & COO for GE Capital ITS Spain, and general manager for GE Clinical Services in the EMEA region.

Continue reading →

MedLumics appoints Dr. Wolfgang Reim as Independent Director

Madrid, June 10th, 2013 – MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of the industry expert Wolfgang Reim as Independent Director for its board.

“Wolfgang’s experience in the process of creation, development and commercialization of medical technology, his global vision of the market of medical imaging and his proven strategic skills will contribute to turn the technology innovation developed by MedLumics into clinical value”, said Eduardo Margallo, President and co-founder.

Dr. Reim studied Mathematics and Physics at ETH Zürich, Switzerland, obtaining his PhD in experimental physics at the same institution. He brings a valuable experience to MedLumics as a result of the broad range of executive responsibilities held at leading companies in the medical technology industry. He was CEO at Dräger Medical AG & Co. KG and a member of the Board of Directors at Drägerwerk AG for 7 years. Previously, he was president for the Ultrasound Division at Siemens Healthcare, based in the US, and was holding top executive positions in areas such as magnetic resonance imaging, mammography, urology, lithotripsy, surgery, portable X rays and accessories before. At the beginning of his career, this expert worked at the R&D centers of IBM and Siemens. Currently, Wolfgang Reim is a member of the Board of Directors at Carl Zeiss Meditec AG, GN Store Nord A/S, Ondal Medical Systems and Elekta AB.

Continue reading →